Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma

Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma

This study aimed to fill this gap by comparing the effectiveness of intravenous magnesium sulfate versus terbutaline in children with acute asthma exacerbations, providing evidence-based guidance for clinicians in emergency settings.

Despite the established roles of both magnesium sulfate and terbutaline in the management of severe asthma exacerbations, there is limited comparative data on their efficacy and safety in the pediatric population. Understanding the relative benefits and risks of these therapies is crucial for optimizing treatment strategies and improving patient outcomes.

Inclusion Criteria:

• Known cases of asthma
• Minimum duration of asthma as 6 months
• Presenting with acute exacerbation of asthma
• Requiring emergency treatment.

Exclusion Criteria:

• Children having chronic respiratory diseases (cystic fibrosis, bronchopuonary dysplasia)
• Children with cardiac diseases
• Children who were hospitalized in the past 2-weeks due to any reasons
• Children using oral or intravenous corticosteroids or other systemic medications
• Children who were unable to undergo PEFR measurements due to any reasons